Treatment of Acute Pancreatitis

1. Diagnosis & Severity Assessment

1. Characteristic epigastric pain (often radiating to the back)
2. Serum lipase or amylase >3x upper limit of normal (lipase preferred - higher sensitivity/specificity)
3. Characteristic findings on imaging (CT/MRI)

2. Fluid Resuscitation (MOST IMPORTANT EARLY INTERVENTION)

• Lactated Ringer's (LR) is preferred over normal saline (NS)
  • LR is more physiologic (balanced electrolyte solution)
  • LR may provide anti-inflammatory effects via lactate-mediated mechanisms
  • A 2025 meta-analysis of 6 RCTs (n=1,500 patients) showed LR vs. NS: significantly lower risk of moderate-to-severe AP (OR 0.48; 95% CI 0.34-0.67), shorter hospital stay, lower ICU admission rate (RR 0.42), and fewer local complications (Zhao et al., Int J Surg 2025, PMID 40085761)
• Rate: Aggressive resuscitation - typically 250-500 mL/h during the first 12-24 hours in moderate-severe disease; careful goal-directed therapy to avoid overhydration
• Titrate to: urine output >0.5 mL/kg/h, HR <100, MAP >65 mmHg, BUN trending down

3. Pain Management

• Adequate analgesia is essential; IV opioids (morphine, hydromorphone, fentanyl) are widely used and are safe
• NSAIDs and acetaminophen can supplement but are often insufficient alone in acute presentations
• There is no evidence that one analgesic is superior to another specifically for pancreatitis
• Epidural analgesia is an option in severe cases

4. Nutrition

• Mild AP: Oral diet should be restarted as soon as it is tolerated (often within 24-48 hours). There is no need to wait until pain resolves or amylase normalizes.
• Moderate-severe AP:
  • Early enteral nutrition within 24-72 hours of admission is associated with decreased mortality, organ failure, and infectious complications vs. delayed nutrition
  • Nasogastric (NG) or nasojejunal (NJ) tube feeding - RCTs show no significant difference in outcomes between gastric vs. jejunal delivery, so a nasogastric tube is acceptable
  • NPO initially if there is ileus or if the patient cannot tolerate any intake
  • TPN (parenteral nutrition) is reserved for cases where enteral feeding is not tolerated (refractory vomiting, intestinal obstruction, high-output fistula)
• Enteral nutrition maintains gut barrier function, reduces bacterial translocation, and reduces risk of infectious complications

5. Antibiotics

• Prophylactic antibiotics are NOT indicated in acute pancreatitis - this includes even severe or necrotizing pancreatitis without evidence of infection
• Harrison's (2025 ed.): "Prophylactic antibiotics are no longer recommended for severe acute pancreatitis"
• Antibiotics ARE indicated for:
  • Documented infected pancreatic necrosis (confirmed by FNA or gas on CT, or clinical deterioration with fever/leukocytosis)
  • Cholangitis (ascending cholangitis complicating biliary pancreatitis)
  • Other clear sources of bacterial sepsis
• Preferred agents for infected necrosis: carbapenems (imipenem, meropenem) or fluoroquinolones + metronidazole (good pancreatic tissue penetration)

6. Role of ERCP

• ERCP is indicated in:
  • Acute cholangitis complicating gallstone pancreatitis (urgent, within 24-72 hours)
  • Biliary obstruction with evidence of persistent common bile duct stones
• ERCP is NOT indicated in mild biliary pancreatitis without cholangitis or persistent biliary obstruction (does not improve outcomes and risks complications)
• Rectal indomethacin (NSAIDs) or pancreatic duct stenting is used to prevent post-ERCP pancreatitis in high-risk patients

7. Management of Complications

Pancreatic Necrosis

• Minimally invasive approach preferred (step-up approach)
  1. CT/EUS-guided percutaneous or endoscopic drainage as first step
  2. Video-assisted retroperitoneal debridement (VARD) or endoscopic necrosectomy if drainage fails
  3. Open surgical necrosectomy - last resort (high morbidity/mortality)
• Intervention ideally delayed >4 weeks to allow "walled-off necrosis" (WON) to mature (better defined walls, safer to drain)
• FNA is now used less routinely; clinical judgment + CT findings guide decisions

Pseudocyst

• Most resolve spontaneously
• Drainage indicated if: symptomatic (pain, gastric outlet obstruction), infection, enlarging, or >6 weeks without resolution
• Endoscopic (EUS-guided cyst-gastrostomy or cyst-duodenostomy) is preferred over surgical drainage

Pancreatic Ascites/Pleural Effusion

• From ductal disruption; ERCP with stenting ± somatostatin analogue

8. Special Situations

Biliary/Gallstone Pancreatitis

• Cholecystectomy should be performed before discharge (or at least during the same hospitalization) in mild disease to prevent recurrence
• In severe disease, cholecystectomy is deferred until recovery

Hypertriglyceridemia-induced Pancreatitis

• Insulin infusion or plasmapheresis to rapidly lower triglycerides (target <500 mg/dL)
• Fibrates and dietary fat restriction for long-term prevention

Alcohol-induced Pancreatitis

• Alcohol cessation counseling and treatment (reduces recurrence and progression to chronic pancreatitis)

9. ICU Indications

• Persistent organ failure (renal, respiratory, cardiovascular)
• APACHE II score >8 or Ranson score >3 at 48 hours
• Clinical deterioration despite initial management
• Septic shock from infected necrosis

10. Summary of Key Guideline Recommendations (2024-2025)

1. LR preferred over NS for fluid resuscitation
2. Early enteral nutrition within 24-72 hours
3. No prophylactic antibiotics in the absence of infection
4. Minimally invasive, step-up approach for infected necrosis
5. Cholecystectomy before discharge for biliary pancreatitis
6. ERCP only for cholangitis/biliary obstruction
7. Conservative management for sterile complications whenever possible

• Rosen's Emergency Medicine, 10th ed. - Chapter 77
• Maingot's Abdominal Operations - Chapter 55 (Complications of AP)
• Harrison's Principles of Internal Medicine, 22nd ed. (2025) - Chapter 7.39
• Washington Manual of Medical Therapeutics - Nutrition section
• ACG Guidelines 2024 (PMID 38857482)
• IAP/APA/EPC/IPC/JPS Revised Guidelines 2025 (PMID 40651900)
• Zhao et al., LR vs NS meta-analysis, Int J Surg 2025 (PMID 40085761)